Drug Profile


Alternative Names: OC-2

Latest Information Update: 16 May 2006

Price : $50

At a glance

  • Originator Oculon
  • Class Antihyperlipidaemics; Small molecules; Vitamins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cataracts

Most Recent Events

  • 16 May 2006 Discontinued - Phase-III for Cataracts in USA (Ophthalmic)
  • 20 Feb 1997 Phase-III clinical trials for Cataracts in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top